News
SUPN
30.75
+0.23%
0.07
Third Avenue Small Cap Value Fund Q2 2024 Commentary
Third Avenue Small Cap Value Fund returned -5.98% during the second quarter of 2024, compared to a return of -3.64% for the Russell 2000 Value Index. The Russell 1000 Index has outperformed the small-cap index by 12.50% in the first half of 2024. Amazon.com Inc. Is one of the greatest success stories of our lifetime.
Seeking Alpha · 1d ago
Supernus Pharmaceuticals Currently Up 13 Consecutive Days, on Track for Record Winning Streak -- Data Talk
Dow Jones · 4d ago
Weekly Report: what happened at SUPN last week (0715-0719)?
Weekly Report · 4d ago
Aristotle Capital Small/Mid Cap Equity Q2 2024 Commentary
Seeking Alpha · 07/18 11:40
Weekly Report: what happened at SUPN last week (0708-0712)?
Weekly Report · 07/15 11:14
Supernus Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for SUPN
NASDAQ · 07/11 18:14
Weekly Report: what happened at SUPN last week (0701-0705)?
Weekly Report · 07/08 11:16
Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout
Seeking Alpha · 07/02 11:30
Weekly Report: what happened at SUPN last week (0624-0628)?
Weekly Report · 07/01 11:16
Weekly Report: what happened at SUPN last week (0617-0621)?
Weekly Report · 06/24 11:24
Weekly Report: what happened at SUPN last week (0610-0614)?
Weekly Report · 06/17 11:15
Weekly Report: what happened at SUPN last week (0603-0607)?
Weekly Report · 06/10 11:17
Weekly Report: what happened at SUPN last week (0527-0531)?
Weekly Report · 06/03 11:20
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Jack Khattar will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Barchart · 05/30 15:25
Supernus Pharmaceuticals Enters Oversold Territory (SUPN)
NASDAQ · 05/28 20:33
Weekly Report: what happened at SUPN last week (0520-0524)?
Weekly Report · 05/27 11:25
Stifel Nicolaus Sticks to Its Hold Rating for Supernus Pharmaceuticals (SUPN)
TipRanks · 05/24 11:06
Piper Sandler Sticks to Its Buy Rating for Supernus Pharmaceuticals (SUPN)
TipRanks · 05/24 10:46
SUPERNUS ANNOUNCES PROMISING INTERIM DATA FROM ONGOING OPEN-LABEL PHASE 2A STUDY OF SPN-817 IN EPILEPSY
Reuters · 05/23 20:05
SUPERNUS PHARMACEUTICALS INC: SPN-817 WAS SAFE AND HAD ACCEPTABLE TOLERABILITY
Reuters · 05/23 20:05
More
Webull provides a variety of real-time SUPN stock news. You can receive the latest news about Supernus Pharma through multiple platforms. This information may help you make smarter investment decisions.
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.